Safety assessment of DPI-4452, a cyclic peptide targeting Carbonic Anhydrase IX

Poster presented at ACT 43rd Annual Meeting

Inês Borrego¹, Frédéric Massière¹, Antoine Attinger¹, Anne Schumann ², Aileen Hoehne ², Frank Osterkamp ², Ulf Andersson¹

¹Debiopharm, Lausanne, SWITZERLAND
² 3B Pharmaceuticals GmbH, Berlin, GERMANY

Introduction

The transmembrane metalloprotease Carbonic Anhydrase IX (CAIX) represents an attractive diagnostic and therapeutic target in hypoxic solid tumors such as Colorectal Cancer (CRC) and clear cell Renal Cell Carcinoma (ccRCC), with limited expression in healthy organs.

DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage that can be labelled with different radionuclides for theranostic purposes.